These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 20200277)

  • 1. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis.
    Unsinger J; McGlynn M; Kasten KR; Hoekzema AS; Watanabe E; Muenzer JT; McDonough JS; Tschoep J; Ferguson TA; McDunn JE; Morre M; Hildeman DA; Caldwell CC; Hotchkiss RS
    J Immunol; 2010 Apr; 184(7):3768-79. PubMed ID: 20200277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia.
    Shindo Y; Fuchs AG; Davis CG; Eitas T; Unsinger J; Burnham CD; Green JM; Morre M; Bochicchio GV; Hotchkiss RS
    J Leukoc Biol; 2017 Feb; 101(2):543-554. PubMed ID: 27630218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on "IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis" and comment on "IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis".
    Carrol ED
    J Immunol; 2010 Jul; 185(2):789; author reply 789-90. PubMed ID: 20601609
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.
    Inoue S; Unsinger J; Davis CG; Muenzer JT; Ferguson TA; Chang K; Osborne DF; Clark AT; Coopersmith CM; McDunn JE; Hotchkiss RS
    J Immunol; 2010 Feb; 184(3):1401-9. PubMed ID: 20026737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis.
    Unsinger J; Walton AH; Blood T; Tenney DJ; Quigley M; Drewry AM; Hotchkiss RS
    J Leukoc Biol; 2021 Apr; 109(4):697-708. PubMed ID: 33264454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-7 restores lymphocyte functions in septic patients.
    Venet F; Foray AP; Villars-Méchin A; Malcus C; Poitevin-Later F; Lepape A; Monneret G
    J Immunol; 2012 Nov; 189(10):5073-81. PubMed ID: 23053510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis.
    Kasten KR; Prakash PS; Unsinger J; Goetzman HS; England LG; Cave CM; Seitz AP; Mazuski CN; Zhou TT; Morre M; Hotchkiss RS; Hildeman DA; Caldwell CC
    Infect Immun; 2010 Nov; 78(11):4714-22. PubMed ID: 20823197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhodiola rosea suppresses thymus T-lymphocyte apoptosis by downregulating tumor necrosis factor-α-induced protein 8-like-2 in septic rats.
    Liu MW; Su MX; Zhang W; Zhang LM; Wang YH; Qian CY
    Int J Mol Med; 2015 Aug; 36(2):386-98. PubMed ID: 26063084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis.
    Schwulst SJ; Grayson MH; DiPasco PJ; Davis CG; Brahmbhatt TS; Ferguson TA; Hotchkiss RS
    J Immunol; 2006 Jul; 177(1):557-65. PubMed ID: 16785553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory intervention with Gamma interferon in mice with sepsis.
    Wang Y; Kong BB; Yang WP; Zhao X; Zhang R
    Life Sci; 2017 Sep; 185():85-94. PubMed ID: 28711488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-37 Enhances the Suppressive Activity of Naturally Occurring CD4
    Wang DW; Dong N; Wu Y; Zhu XM; Wang CT; Yao YM
    Sci Rep; 2016 Dec; 6():38955. PubMed ID: 27941849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.
    Zhang Z; Li X; Guo J; Xu F; He Q; Zhao Y; Yang Y; Gu S; Zhang Y; Wu L; Chang C
    Eur J Haematol; 2013 May; 90(5):375-84. PubMed ID: 23331180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotactic responses of IL-4-, IL-10-, and IFN-gamma-producing CD4+ T cells depend on tissue origin and microbial stimulus.
    Debes GF; Dahl ME; Mahiny AJ; Bonhagen K; Campbell DJ; Siegmund K; Erb KJ; Lewis DB; Kamradt T; Hamann A
    J Immunol; 2006 Jan; 176(1):557-66. PubMed ID: 16365450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease.
    Ito H; Hirotani T; Yamamoto M; Ogawa H; Kishimoto T
    J Gastroenterol; 2002 Nov; 37 Suppl 14():56-61. PubMed ID: 12572867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.
    Melchionda F; Fry TJ; Milliron MJ; McKirdy MA; Tagaya Y; Mackall CL
    J Clin Invest; 2005 May; 115(5):1177-87. PubMed ID: 15841203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo.
    Taub DD; Anver M; Oppenheim JJ; Longo DL; Murphy WJ
    J Clin Invest; 1996 Apr; 97(8):1931-41. PubMed ID: 8621778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-7 and Its Beneficial Role in Sepsis-Induced T Lymphocyte Dysfunction.
    de Roquetaillade C; Monneret G; Gossez M; Venet F
    Crit Rev Immunol; 2018; 38(6):433-451. PubMed ID: 31002599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects.
    Pinsonneault S; El Bassam S; Mazer B; Cruikshank WW; Laberge S
    J Allergy Clin Immunol; 2001 Mar; 107(3):477-82. PubMed ID: 11240948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt decreases lymphocyte apoptosis and improves survival in sepsis.
    Bommhardt U; Chang KC; Swanson PE; Wagner TH; Tinsley KW; Karl IE; Hotchkiss RS
    J Immunol; 2004 Jun; 172(12):7583-91. PubMed ID: 15187138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.